The ability to successfully translate basic research in leukemia to the clinical setting, as well as to better understand the relevance of observed clinical phenomena through laboratory-based research, is greatly facilitated by the availability of an extensive repository of tissue samples, with accompanying complete pathologic and clinical data, procured from leukemia patients. The OSUCCC Leukemia Tissue Bank Shared Resource (LTBSR), separate and distinct from the CALGB Leukemia Tissue Bank, is a shared resource established in 1997 with over 4,500 patient samples procured from 762 consented leukemia patients at OSU. The infrastructure of the OSUCCC LTBSR is well-established and is directly under our leadership. Specifically we have a large leukemia tissue repository, including both leukemic tissue and normal tissue germ line DNA, accompanied in all cases with complete pathologic, cytogenetic and clinical data for ready correlation of clinical and biological results. In addition, all the essentials of effective leukemia tissue bank management, including the activities of tissue collection, quality control of specimens, tissue storage, procurement of initial and follow-up samples and their pathology and clinical information, data entry and database management, and patient consent and confidentiality are very well developed. Furthermore, the procedures for prioritizing and distributing tissue to a large base of investigators within the OUCCC are effectively in place. Finally, our success in managing this large leukemia tissue resource can be seen in the documented sample collection for and sample distribution to all leukemia researchers within the CCC and 28 publications where the OSUCCC LTBSR has played a significant role. Against this background, we believe that this Shared Resource will function well in the support of the research mission of the OSUCCC in )roducing high-quality basic and clinical research in hematological malignancy. Currently the OSUCCC _TBSR is funded solely with OSUCCC/institutional support.
The Specific Aims of this Shared Resource are, therefore, to: 1) Continue to provide a central collection, processing and a state-of-the-art repository for samples collected from leukemia patients treated on OSU protocols, and 2) Provide materials from the LTBSR to interested investigators within OSUCCC, as well as to outside interested investigators involved in collaborative studies with OSU, who examine relevant cellular and molecular properties of leukemia.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-33
Application #
7630234
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2007-12-01
Budget End
2008-11-30
Support Year
33
Fiscal Year
2008
Total Cost
$66,366
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Ozawa, Patricia Midori Murobushi; Alkhilaiwi, Faris; Cavalli, Iglenir João et al. (2018) Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells. Breast Cancer Res Treat 172:713-723
Ngankeu, Apollinaire; Ranganathan, Parvathi; Havelange, Violaine et al. (2018) Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia. Oncotarget 9:4354-4365
Lopez, Cecilia M; Yu, Peter Y; Zhang, Xiaoli et al. (2018) MiR-34a regulates the invasive capacity of canine osteosarcoma cell lines. PLoS One 13:e0190086
Victor, Aaron R; Weigel, Christoph; Scoville, Steven D et al. (2018) Epigenetic and Posttranscriptional Regulation of CD16 Expression during Human NK Cell Development. J Immunol 200:565-572
Lampis, Andrea; Carotenuto, Pietro; Vlachogiannis, Georgios et al. (2018) MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma. Gastroenterology 154:1066-1079.e5
Le Gallo, Matthieu; Rudd, Meghan L; Urick, Mary Ellen et al. (2018) The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas. Cancer 124:65-73
Jones, Jeffrey A; Mato, Anthony R; Wierda, William G et al. (2018) Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol 19:65-75
Baldassari, Federica; Zerbinati, Carlotta; Galasso, Marco et al. (2018) Screen for MicroRNA and Drug Interactions in Breast Cancer Cell Lines Points to miR-126 as a Modulator of CDK4/6 and PIK3CA Inhibitors. Front Genet 9:174
Yang, Xiaosong; Pan, You; Qiu, Zhaojun et al. (2018) RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells. Clin Cancer Res 24:1629-1643
Latchana, Nicholas; DiVincenzo, Mallory J; Regan, Kelly et al. (2018) Alterations in patient plasma microRNA expression profiles following resection of metastatic melanoma. J Surg Oncol 118:501-509

Showing the most recent 10 out of 2602 publications